加载中
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
前收盘价
US$11.70
+US$0.58 · +5.22%
盘前
US$11.92
+US$0.22 · +1.88%
10月12日 5:36 ET
盘中时间采用ET。市场数据可能有所延迟。
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
日内区间
当前US$11.70
52周区间
当前US$11.70
盘中时间采用ET。市场数据可能有所延迟。
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
日内区间
当前US$11.70
52周区间
当前US$11.70
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6855.6万 USD | 7420.5万 USD | 8618万 USD | 16.16亿 USD | 10.95亿 USD |
| 销货成本 | 1170.6万 USD | 1540.4万 USD | 2221.6万 USD | 1.62亿 USD | 7167.6万 USD |
| 毛利 | 5685万 USD | 5880.1万 USD | 6396.4万 USD | 14.54亿 USD | 10.24亿 USD |
| 研究与开发 | 4.33亿 USD | 4.63亿 USD | 5.51亿 USD | 4.68亿 USD | 4.42亿 USD |
| 销售、一般及管理费用 | 9207.4万 USD | 1.19亿 USD | 1.74亿 USD | 1.53亿 USD | 1.61亿 USD |
| 营业费用 | 5.25亿 USD | 5.82亿 USD | 7.25亿 USD | 6.21亿 USD | 6.03亿 USD |
| 利息收入 | 4023.8万 USD | 7180.9万 USD | 8699万 USD | 2809.2万 USD | 43.9万 USD |
| 折旧和摊销 | 1168万 USD | 1455.9万 USD | 1945.1万 USD | 1549.2万 USD | 1198.3万 USD |
| 营业利润 | −4.68亿 USD | −5.23亿 USD | −6.61亿 USD | 8.33亿 USD | 4.21亿 USD |
| 净利润 | −4.38亿 USD | −5.22亿 USD | −6.15亿 USD | 5.16亿 USD | 5.29亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$23.50
上涨空间 100.85%报告持有此股票敞口的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR8425.73万0.08%1031.91亿 USD0.06%US$137.55+0.17%
Vanguard Morningstar Total Stock Market ETFVTI5302.2万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM3994.57万0.05%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB3819.45万0.02%1853亿 USD0.03%US$289.48+0.64%
State Street SPDR S&P Biotech ETFXBI2869.57万0.29%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Morningstar Small-Cap Growth ETFVBK2187.58万0.05%447亿 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF1547.77万0.02%954亿 USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS1322.98万0.04%338.69亿 USD0.31%US$78.35+0.32%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
